Clinical TrialsSearch results
Number of results: 605
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- Phase II, multicenter, open-label study of Trastuzumab derxtecan in patients with HER2-expressing recurrent and or metastatic salivary gland carcinoma
- HER2-expressing recurrent and/or metastatic salivary gland carcinoma
- Hirotoshi Akita
- 2021-06-17
Recruiting
- [M20-178] Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Best Available Therapy
- Myelofibrosis
- Okubo Sumiko
- 2021-06-09
Recruiting
- A clinical study to evaluate 5-ALA for pancreatobiliary cancer
- Biliary cancer, pancreatic cancer
- Tanaka Kimitaka
- 2021-06-04
Other
- 38-501 : BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey (ML)
- radically unresectable malignant melanoma with a BRAF gene mutation
- Kido Tomoyuki
- 2021-05-25
Recruiting
- 38-502:BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey(CRC)
- unresectable advanced or recurrent BRAF-mutant colorectal cancer
- Kido Tomoyuki
- 2021-05-25
Recruiting
- 40-301 : Special Drug Use-Results Survey of ADLUMIZ
- Cancer cachexia: non-small cell lung cancer, gastric cancer, pancreatic cancer, large intestine canc
- Kido Tomoyuki
- 2021-05-25
Recruiting
- 43-301 : Special Drug Use-Results Survey of ONGENTYS
- Parkinson's disease
- Kido Tomoyuki
- 2021-05-25
Completed
- A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Severe Atopic Dermatitis.
- Moderate to severe Atopic dermatitis (AD)
- Changliang Zhang
- 2021-05-25
Recruiting
- A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Minal Mehta, MBBS
- 2021-05-18
Recruiting
- A phase3b study of KTE-C19 (at the time of manufacture of commercially available products) in patients with the indication on the package insert
- DLBCL, PMBCL, TFL, HGBCL
- Aso Hiroya
- 2021-05-11